Navigating the Regulatory Path to the First mRNA Therapeutic Approvals
As mRNA technology accelerates beyond vaccines into oncology, rare disease, and cell engineering, one defining question remains: how do we get the next wave of mRNA therapeutics across the regulatory finish line?
In 2026, regulatory strategy is no longer a downstream consideration. With complex modalities, novel delivery methods, and personalised approaches entering the clinic, early and continuous regulatory alignment has become mission‑critical.
This is exactly why regulatory leadership takes centre stage at the 6th mRNA‑Based Therapeutics Summit, uniting FDA, EMA, and MHRA voices with industry pioneers shaping first‑in‑class approvals.
Why Regulation Is the Defining Bottleneck for mRNA’s Next Chapter
Unlike traditional biologics, mRNA therapeutics challenge existing regulatory frameworks across:
CMC control strategies
Potency and analytical methods
Manufacturing changes across the lifecycle
Personalised and patient‑specific production models
Regulators are actively evolving guidance – but developers must understand where alignment exists, where divergence remains, and how to proactively build regulatory confidence.
At this year’s summit, senior regulators will directly address:
- What approval‑ready mRNA programs need to demonstrate today
- How expectations differ across vaccines, oncology, and gene therapies
- How to minimize late‑stage CMC changes and approval delays
Hear Directly from Global Regulatory Authorities
The 2026 agenda features rare, front‑row access to regulators defining how mRNA therapies will reach patients:
Key Sessions Include
- A Regulatory Perspective Towards the First mRNA Therapeutic Approval
- MHRA Guidelines on Individualised mRNA Cancer Immunotherapies
- Reviewing the Global Regulatory CMC Guideline Landscape for mRNA
These discussions move beyond theory – providing practical guidance sponsors can apply immediately to clinical and commercial programs.
Why This Matters Now
With mRNA oncology programs advancing, in vivo CAR‑T entering clinical validation, and personalised cancer vaccines gathering momentum, the first non‑vaccine mRNA approvals are within reach.
Companies that succeed will be those that:
- Engage regulators early
- Build robust, flexible CMC strategies
- Design with global market access in mind
The 6th mRNA‑Based Therapeutics Summit is where these strategies are being shaped.
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights on the mRNA innovations during our packed agenda, interactive roundtables, and new CEOs & investor panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of mRNA biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.